Dr. Jak Knowles joined Leaps by Bayer as Vice President of Venture Investments in 2018.
Prior to joining Bayer, Jak served as CEO of CytoSen Therapeutics, developing Natural Killer cell immunotherapies for oncology indications. Serving as interim-CEO, Jak co-founded and launched Exonics Therapeutics, a CRISPR gene-editing company in 2016.
Jak has a medical degree from Stanford University where he graduated with honors in biomedical research. Jak currently serves on the Board of Directors for Century Therapeutics, Pyxis Oncology, Metagenomi Technologies, and NewLeaf Symbiotics.